Gilead Sciences, Inc. (NASDAQ:GILD) has put together a nice run of late. The GILD stock price today sits 24% higher than it did as recently as June, when the stock hit a three-year low. There is some good news here. As InvestorPlace’s …
With nothing more than a quick view of its chart and a passing glance at the headlines, it would be easy to decide Gilead Sciences, Inc. (NASDAQ:GILD) is best left avoided. The GILD stock price took a fairly big tumble after the release of …
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it …
Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018. This newly minted tax reform, after all, should spur a flurry of mergers and acquisitions (M&A) activity by …
Given the competitive threats, Baird dismissed Gilead's move into oncology as "incrementally negative" for the stock. Mizuho Securities did a quick straw poll of investors and concluded that "60% of respondents believe Gilead overpaid …
The GILD stock price today sits 24% higher than it did as recently as June, when the stock hit a three-year low. There is some good news here. As InvestorPlace’s Chris Lau pointed out, the acquisition of Kite Pharma and its CAR-T …
With $12.2 billion in trailing-12-month earnings, and $13.4 billion in trailing free cash flow, Gilead Sciences remains a very profitable stock. Valuation-wise, Gilead stock costs 8.7 times earnings, but only 7.9 times free cash flow (FCF). That …